Lantheus Holdings, Inc. (NASDAQ:LNTH) Holdings Increased by Portolan Capital Management LLC

Portolan Capital Management LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 670,881 shares of the medical equipment provider’s stock after buying an additional 38,776 shares during the quarter. Lantheus makes up about 5.3% of Portolan Capital Management LLC’s holdings, making the stock its biggest holding. Portolan Capital Management LLC owned 0.96% of Lantheus worth $73,629,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Signaturefd LLC grew its position in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC grew its position in Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after purchasing an additional 100 shares during the last quarter. UMB Bank n.a. grew its position in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC grew its position in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Lantheus by 4.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider’s stock valued at $533,000 after acquiring an additional 287 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on LNTH shares. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial restated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. Finally, JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $125.71.

Lantheus Trading Down 1.2 %

NASDAQ LNTH opened at $88.51 on Wednesday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The stock has a market cap of $6.15 billion, a price-to-earnings ratio of 14.73 and a beta of 0.45. The company’s 50 day moving average is $100.44 and its two-hundred day moving average is $97.49.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.